Barclays PLC Sells 184,837 Shares of Tenaya Therapeutics, Inc. (NASDAQ:TNYA)

Barclays PLC lessened its position in Tenaya Therapeutics, Inc. (NASDAQ:TNYA) by 68.6% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 84,627 shares of the company’s stock after selling 184,837 shares during the period. Barclays PLC owned approximately 0.11% of Tenaya Therapeutics worth $121,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in TNYA. JPMorgan Chase & Co. increased its stake in Tenaya Therapeutics by 20,670.3% in the 4th quarter. JPMorgan Chase & Co. now owns 5,155,596 shares of the company’s stock valued at $7,373,000 after buying an additional 5,130,774 shares during the last quarter. Sei Investments Co. acquired a new stake in Tenaya Therapeutics during the 4th quarter worth approximately $100,000. Virtu Financial LLC acquired a new position in shares of Tenaya Therapeutics in the fourth quarter valued at about $150,000. Commonwealth Equity Services LLC bought a new position in shares of Tenaya Therapeutics during the fourth quarter worth approximately $64,000. Finally, abrdn plc lifted its position in shares of Tenaya Therapeutics by 9.1% during the 4th quarter. abrdn plc now owns 600,700 shares of the company’s stock valued at $859,000 after acquiring an additional 50,000 shares during the period. 90.54% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

TNYA has been the topic of a number of research analyst reports. Canaccord Genuity Group reduced their target price on Tenaya Therapeutics from $18.00 to $6.00 and set a “buy” rating on the stock in a report on Thursday, March 13th. Morgan Stanley dropped their price target on shares of Tenaya Therapeutics from $15.00 to $5.00 and set an “overweight” rating on the stock in a research report on Wednesday, March 12th. Chardan Capital restated a “buy” rating and set a $9.00 price target on shares of Tenaya Therapeutics in a report on Friday, May 9th. Finally, HC Wainwright reissued a “buy” rating and issued a $5.00 price objective on shares of Tenaya Therapeutics in a research note on Friday, April 25th. Seven analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $6.25.

Insider Buying and Selling at Tenaya Therapeutics

In other Tenaya Therapeutics news, major shareholder Group Gp Lp Column III acquired 35,714,284 shares of the stock in a transaction dated Wednesday, March 5th. The shares were purchased at an average price of $0.70 per share, for a total transaction of $24,999,998.80. Following the purchase, the insider now directly owns 49,313,559 shares of the company’s stock, valued at approximately $34,519,491.30. This trade represents a 262.62% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Over the last 90 days, insiders sold 19,621 shares of company stock worth $10,595. 32.76% of the stock is owned by insiders.

Tenaya Therapeutics Stock Down 1.6%

Shares of TNYA stock opened at $0.39 on Thursday. The firm has a market cap of $33.97 million, a P/E ratio of -0.27 and a beta of 2.99. The business has a 50-day moving average price of $0.52 and a two-hundred day moving average price of $1.34. Tenaya Therapeutics, Inc. has a 12-month low of $0.36 and a 12-month high of $4.78.

Tenaya Therapeutics (NASDAQ:TNYA) last posted its earnings results on Wednesday, May 7th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.06). As a group, research analysts expect that Tenaya Therapeutics, Inc. will post -1.35 EPS for the current fiscal year.

Tenaya Therapeutics Company Profile

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.